Sensei Biotherapeutics (NASDAQ:SNSE) Coverage Initiated at BTIG Research

Investment analysts at BTIG Research started coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 382.03% from the company’s previous close.

Several other research analysts have also recently weighed in on the stock. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Finally, Citigroup started coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $48.00.

Sensei Biotherapeutics Trading Down 9.7%

Shares of SNSE stock opened at $11.41 on Thursday. Sensei Biotherapeutics has a 12-month low of $5.60 and a 12-month high of $36.76. The firm’s 50 day moving average is $24.13 and its 200 day moving average is $18.88. The stock has a market capitalization of $15.29 million, a P/E ratio of -0.08 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc sold 8,151 shares of the firm’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $31.01, for a total transaction of $252,762.51. Following the sale, the insider directly owned 133,986 shares in the company, valued at $4,154,905.86. This trade represents a 5.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. The trade was a 16.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have bought 46,980 shares of company stock worth $1,341,669 and have sold 48,067 shares worth $1,204,939. 7.00% of the stock is owned by company insiders.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the period. Bank of America Corp DE raised its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at $4,188,000. Finally, Vivo Capital LLC bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.